No near-term binary catalyst — the next major event is TX2100 Phase 1a data in Q3 2026, followed by TX45 APEX topline in late Q4 2026/early Q1 2027. Monitor cash burn trajectory and any early efficacy signals from the ongoing Phase 2 trials. The $236.9M cash position provides a long runway, reducing near-term dilution risk.
Price Chart
Executive Summary
Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by increased R&D spend on TX45 and TX2100 trials. Cash burn was $16.9M in the quarter, leaving $236.9M in cash (runway into Q4 2028). The stock will move on pipeline milestones, not the financials — TX45 APEX Phase 2 topline in late Q4 2026/early Q1 2027 and TX2100 Phase 1a results in Q3 2026 are the key catalysts.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $25.2M ($1.34/share) vs $15.9M ($0.93/share) in Q1 2025
- Cash and equivalents $236.9M as of March 31, 2026, down from $253.8M at Dec 31, 2025
- R&D expense $20.9M, up 60% YoY from $13.0M, driven by TX45 Phase 2 and TX2100 Phase 1a costs
- TX45 APEX Phase 2 enrollment nearing completion; topline results expected late Q4 2026 or early Q1 2027
- TX2100 Phase 1a in HHT dosed 4 cohorts; topline results expected by end of Q3 2026
- TX45 ALPINE Phase 2 in PH-ILD initiated with first site activated in February 2026
- Cash runway projected into Q4 2028, covering both Phase 2 readouts and TX2100 advancement
Financial Impact
Net loss widened $9.3M YoY to $25.2M; cash burn $16.9M in Q1 2026
Risk Factors
- Phase 2 failure for TX45 in PH-HFpEF or PH-ILD would significantly impair pipeline value
- TX2100 Phase 1a safety/tolerability miss could derail the HHT program
- Cash burn rate is accelerating (R&D up 60% YoY); any trial delays could pressure runway assumptions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290500 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | 144 | $36.47 | awaiting T+60 | — | $19.95 (−45.30%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.34 $30.75 | ▲ +4.81% | ▲ +0.41% | $19.95 (−32.00%) |
May 7, 2026 24w ago | 8-K | $29.00 $29.17 | ▼ −0.59% | ▲ +4.25% | $19.95 (+31.21%) |
May 7, 2026 24w ago | Press Release | $29.00 $29.17 | ▲ +0.59% | ▼ −4.25% | $19.95 (−31.21%) |
Apr 24, 2026 26w ago | DEFA14A | $28.75 $31.59 | ▲ +9.88% | ▲ +5.10% | $19.95 (−30.61%) |
Apr 3, 2026 29w ago | 3 | $29.98 $32.74 | ▲ +9.21% | ▼ −4.26% | $19.95 (−33.46%) |
Mar 6, 2026 33w ago | Insider Cluster | $35.87 $28.89 | ▼ −19.46% | ▼ −32.24% | $19.95 (−44.38%) |
Feb 24, 2026 34w ago | 8-K | $23.11 $28.84 | ▲ +24.79% | ▲ +17.84% | $19.95 (−13.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers